Patents by Inventor Masaru Okabe
Masaru Okabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9700024Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.Type: GrantFiled: April 14, 2015Date of Patent: July 11, 2017Assignees: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Masaru Okabe, Masahito Ikawa, Tadashi Kimura, Keiichi Kumasawa
-
Publication number: 20150264901Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.Type: ApplicationFiled: April 14, 2015Publication date: September 24, 2015Inventors: Masaru OKABE, Masahito IKAWA, Tadashi KIMURA, Keiichi KUMASAWA
-
Patent number: 9029627Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.Type: GrantFiled: March 4, 2011Date of Patent: May 12, 2015Assignees: Fuso Pharmaceutical Industries, Ltd.Inventors: Masaru Okabe, Masahito Ikawa, Tadashi Kimura, Keiichi Kumasawa
-
Publication number: 20140370602Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.Type: ApplicationFiled: July 16, 2014Publication date: December 18, 2014Applicants: FUSO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Masaru OKABE, Masahito IKAWA
-
Patent number: 8815598Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.Type: GrantFiled: July 31, 2006Date of Patent: August 26, 2014Assignees: Fuso Pharmaceutical Industries, Ltd.Inventors: Masaru Okabe, Masahito Ikawa
-
Publication number: 20130198874Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.Type: ApplicationFiled: March 4, 2011Publication date: August 1, 2013Inventors: Masaru Okabe, Masahito Ikawa, Tadashi Kimura, Keiichi Kumasawa
-
Publication number: 20100329987Abstract: The present invention yielded unique monoclonal antibodies that reacted specifically only to sperms after acrosome reaction, and the antigens (OBFs) recognized by the antibodies were identified. The antibodies were found to inhibit fusion between mouse sperms and eggs. Furthermore, OBF gene-knockout mice were created and analyzed to clarify the in vivo functions of OBF. As a result, male OBF gene-knockout mice were shown to be infertile, and their sperms were shown to be able to bind to eggs, but had no fusion ability.Type: ApplicationFiled: April 23, 2010Publication date: December 30, 2010Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Masaru Okabe, Naokazu Inoue
-
Publication number: 20090013418Abstract: The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods.Type: ApplicationFiled: July 31, 2006Publication date: January 8, 2009Inventors: Masaru Okabe, Masahito Ikawa
-
Publication number: 20080025982Abstract: The present invention yielded unique monoclonal antibodies that reacted specifically only to sperms after acrosome reaction, and the antigens (OBFs) recognized by the antibodies were identified. The antibodies were found to inhibit fusion between mouse sperms and eggs. Furthermore, OBF gene-knockout mice were created and analyzed to clarify the in vivo functions of OBF. As a result, male OBF gene-knockout mice were shown to be infertile, and their sperms were shown to be able to bind to eggs, but had no fusion ability.Type: ApplicationFiled: August 31, 2005Publication date: January 31, 2008Inventors: Masaru Okabe, Naokazu Inoue
-
Patent number: 6734295Abstract: An object of the present invention is to provide a modified gene for mammals having expression level, in mammalian cells, tissues, organs or bodies, several times as high as that of phage-derived Cre recombinase. To attain the aforementioned object, the present invention provides a modified Cre recombinase gene for mammals consisting of codons frequently used in mammalian cells.Type: GrantFiled: September 14, 2000Date of Patent: May 11, 2004Assignee: President of Osaka UniversityInventors: Shuji Miyagawa, Masaru Okabe
-
Patent number: 5232834Abstract: A monoclonal or polyclonal antibody having a specific binding property to an antigenic site on the human sperm acrosome, which is produced by a hybridoma obtained by fusion between an antibody-producing mammalian (except human) cell immunized with the antigenic site on the human sperm acrosome and a cell having permanent proliferation potency.Type: GrantFiled: March 14, 1990Date of Patent: August 3, 1993Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Masaru Okabe, Tsutomu Mimura